The outgoing administration proposes letting Medicare cover obesity drugs

The Biden administration on Nov. 26, 2024, proposed a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy (semaglutide) and Zepbound (tirzepatide), the White House announced that day ^[1]. The plan would not have taken effect immediately: it was a proposal, and finalizing it would have fallen to the incoming Trump administration ^[1].

What was proposed

Medicare already covers these medicines, made by Novo Nordisk and Eli Lilly, when they are prescribed for diabetes or heart disease — but not for obesity alone, because the program is prohibited by law from doing so ^[1]. That exclusion for "weight loss" drugs has been in the Part D statute since the benefit began.

Rather than wait for Congress to change the law, Medicare officials aimed to expand coverage to all people with obesity in Medicare and Medicaid by reinterpreting the existing statute ^[1]. In practice, that meant treating obesity as a disease being treated, not simply weight loss, so the exclusion would no longer apply.

STAT reported that the future of the policy was "precarious" because the Biden administration waited so long to start the rulemaking process that the incoming Trump administration would have to finish it ^[1]. The shift also came too late to matter politically for President Biden or Vice President Harris, though it could create public pressure on the new team to carry it forward ^[1].

Several important details are not available in the source material here: the specific eligibility rules CMS would have used, the projected cost to taxpayers and to Part D premiums, the number of beneficiaries who would have gained coverage, and the proposed start date. STAT noted separately that the Congressional Budget Office had examined Medicare spending on GLP-1 weight-loss drugs, but those figures are not included in the reporting available for this story ^[1].

The proposal was never finalized. The record of this development indicates the incoming administration dropped it in April 2025; the November 2024 reporting cited here predates that decision and does not describe it ^[1].

Why it matters for patients

For people on Medicare, this is the difference between a drug being on the formulary and being a cash purchase. Because the statutory exclusion stayed in place, Part D plans generally still cannot pay for semaglutide or tirzepatide when the only reason for the prescription is obesity ^[1]. Coverage continues to hinge on having another approved indication, such as type 2 diabetes or cardiovascular disease ^[1].

That creates a two-track experience among people taking the same molecule. Someone with type 2 diabetes may get Ozempic or Mounjaro covered, while a neighbor with obesity and no qualifying second diagnosis faces list prices or manufacturer cash-pay programs for Wegovy or Zepbound. The proposal would have narrowed that gap for Medicare and Medicaid enrollees ^[1].

It also matters because Medicare and Medicaid decisions ripple outward. Commercial insurers and state Medicaid programs often watch what the federal program does. A finalized rule would have signaled that federal policy treats obesity drugs as medical treatment; leaving the exclusion intact keeps the current patchwork of employer and state coverage decisions in place.

What happens next

• Nov. 26, 2024: The White House announces the proposed expansion for Medicare and Medicaid coverage of Wegovy and Zepbound ^[1].
• January 2025 onward: Authority to finalize or withdraw the proposed rule passes to the incoming administration ^[1].
• April 2025: The proposal is dropped and is not finalized, leaving the statutory exclusion in force.

Any future change would require either a new rulemaking effort by CMS or action by Congress to amend the exclusion. Whether either happens is not yet known from the sources available.